Clinical trial eligibility excludes more Black than white patients
https://www.facingourrisk.org/XRAY/clinical-trial-eligibility
Full article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273372/
Eligibility criteria stating who can and cannot participate in clinical trials are necessary. However, traditional eligibility criteria have led to the exclusion of Black people in pancreatic cancer clinical trials. This exclusion restricts patient access to new drugs and limits the ability to generalize results to the population of patients who will ultimately use the drug. Revising eligibility criteria, especially for patients with pancreatic cancer, may improve clinical trial access among Black people. (Posted 8/23/22)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Am I currently eligible for any clinical trials?
- What can I do to increase my eligibility for clinical trials?
Open Clinical Trials
The following treatment studies are enrolling people diagnosed with pancreatic cancer.
- NCT06545942: Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib. This trial studies an investigational drug called MOMA-313 given alone or together with the PARP inhibitor olaparib for people with advanced cancers, including pancreatic cancer with certain mutations.
- NCT04548752: Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation. This study researches whether adding the drug pembrolizumab to the PARP inhibitor olaparib works better than olaparib alone for treating metastatic pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation.
- NCT06115499: Treating Metastatic BRCA1, BRCA2 or PALB2 Pancreatic Cancer Using a New Combination of Chemotherapy Drugs. This study will compare a 3-drug chemotherapy combination (NABPLAGEM; gemcitabine, cisplatin, nab-paclitaxel) to a 2-drug chemotherapy combination (gemcitabine/nab-paclitaxel) to treat people with pancreatic cancer with a BRCA1, BRCA2 or PALB2 mutation who have pancreatic cancer that has progressed after first-line chemotherapy.
- NCT04858334: Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO). This study compares the usual approach (observation) to treatment for one year with olaparib in patients with a BRCA1, BRCA2 or PALB2 mutation.
- NCT04550494: Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib. This study looks at the safety and effectivenss of the drug talazoparib for treating people with advanced breast, gastric, ovarian, pancreatic or other cancers with an inherited mutation or an acquired mutation in certain DNA repair genes, such as BRCA1, BRCA2, ATM, CHEK2, PALB2 and others.
- NCT05932862: Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors. The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with advanced cancers, including pancreatic cancer.
- NCT04150042: SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells. This study looks at whether melphalan, BCNU, vitamin B12b and vitamin C followed by autologous (self) bone marrow stem cell infusion is safe and effective for treating patients with advanced pancreatic cancer or stage 4, HER2-negative breast cancer for people with a BRCA1, BRCA2 or PALB2 inherited mutation.
Other clinical trials for people with pancreatic cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.